Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy

News Daily News

High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy

Yael L. Maxwell

December 13, 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

News Daily News

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

October 04, 2018

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

Edoxaban Looks Good for Asians With A-fib in Real-world Analysis

News Daily News

Edoxaban Looks Good for Asians With A-fib in Real-world Analysis

August 14, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

Asian Patients With A-fib Don’t Gain Anything From Low-Dose Rivaroxaban

News Daily News

Asian Patients With A-fib Don’t Gain Anything From Low-Dose Rivaroxaban

July 24, 2018

NOACs Particularly Beneficial for Women With A-fib, Study Suggests

News Daily News

NOACs Particularly Beneficial for Women With A-fib, Study Suggests

July 11, 2018

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

News Daily News

Bleeding Risk Increased With NSAID Use in Anticoagulated A-fib Patients: RE-LY Analysis

July 10, 2018

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

News Daily News

NOACs Carry Lower MI Risk vs Warfarin in Real-world Study

June 25, 2018

Oral Anticoagulation Boosts Poststroke Outcomes in Patients With A-fib

News Daily News

Oral Anticoagulation Boosts Poststroke Outcomes in Patients With A-fib

May 18, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

April 27, 2018

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

April 24, 2018

‘Practical Guide’ for NOACs Gets an Update

News Daily News

‘Practical Guide’ for NOACs Gets an Update

March 20, 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

News Conference News ACC 2018

Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4

March 13, 2018

Weighing of Female Sex in Stroke Risk Scores Needs Rethink in A-fib

News Daily News

Weighing of Female Sex in Stroke Risk Scores Needs Rethink in A-fib

February 26, 2018

Experts Debate: Is It ‘Nuts’ to Restart Anticoagulation After Lobar ICH?

News Conference News ISC 2018

Experts Debate: Is It ‘Nuts’ to Restart Anticoagulation After Lobar ICH?

January 30, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.